Skip to main content
SpringerLink
Log in

Obsessive-Compulsive Disorder in Children and Adolescents

Treatment Guidelines

  • Disease Management
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The prevalence of obsessive-compulsive disorder (OCD) is 2 to 3% in children and adolescents. A larger proportion have subthreshold symptoms. The initiation of symptoms may be insidious or more abrupt and children are reluctant to reveal symptoms. The most common obsessions are contamination fears and aggressive/ sexual obsessions while the most common compulsions are repeating, ordering compulsions and washing rituals. Comorbid conditions include major depression, generalised anxiety, separation anxiety and tic disorders. A subgroup of children also have pervasive developmental disorder.

Clinical management is based on careful information gathering, availability of the clinician to the family and illness education. Rating scales such as the Leyton Obsessional Inventory — Children’s Version and the Children’s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) are used to establish baseline symptoms. The CY-BOCS is used to assess severity on follow-up. Organic primary causes of OCD should be investigated.

Cognitive-behavioural therapy is effective in adults and controlled trials are underway in children. Individual and family therapy are adjunct treatment modalities.

Pharmacological interventions are based on the use of nonselective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors such as clomipramine or selective serotonin reuptake inhibitors (SSRIs) fluoxetine, fluvoxamine, paroxetine, sertraline or citalopram. SSRIs are currently the agents of choice to treat paediatric OCD; although clomipramine is as effective as the SSRIs, adverse effects make it a less optimal first-line agent. There are no known efficacy differences between SSRIs. Fluoxetine and sertraline may cause more behavioural activation. Fluoxetine has a longer half-life, while fluvoxamine and sertraline have shorter half-lives. Controlled double-blind studies are available for clomipramine, fluvoxamine (which has US Food and Drug Administration approval for use in OCD with children) and sertraline. Trials are underway for paroxetine and fluoxetine.

Augmentation strategies are appropriate after a full trial with adequate length of treatment and maximum tolerated dosage with one or possibly two SSRIs or clomipramine. Tic-related OCD improves with antipsychotic augmentation. In adolescents, careful addition of an SSRI to clomipramine is an alternative strategy. Lithium and buspirone are not useful in augmentation, clonazepam is possibly beneficial.

Attention should be paid to the cytochrome P450 metabolic pathway that affects the SSRIs when used with other drugs. Current experimental immune therapies in children with autoimmune OCD may provide additional treatment strategies.

With adequate treatment most children with OCD will have a positive response, but long term treatment is indicated in most children with moderate to severe symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zohar AH, Ratzoni G, Pauls DL, et al. An epidemiological study of obsessive-compulsive disorder and related disorders in Israeli adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31(6): 1057–61

    Article  PubMed  CAS  Google Scholar 

  2. Valleni-Basile LA, Garrison CZ, Waller JL, et al. Incidence of obsessive-compulsive disorder in a community sample of young adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35(7): 898–906

    Article  PubMed  CAS  Google Scholar 

  3. Anerican Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998; 37(10 Suppl. ): 27S–45S

    Google Scholar 

  4. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357–81

    Article  PubMed  CAS  Google Scholar 

  5. Breiter HC, Rauch SL. Functional MRI and the study of OCD: from symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala. Neuroimage 1996; 4 (3 Pt 3): S127–S138

    Article  PubMed  CAS  Google Scholar 

  6. Grados MA, Riddle MA, LaBuda M, et al. Obsessive-compulsive disorder in children and adolescents. Int J Psychiatry 1997; 9: 83–97

    Article  Google Scholar 

  7. Swedo SE, Rapoport JL, Leonard H, et al. Obsessive-compulsive disorder in children and adolescents. Clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989; 46(4): 335–41

    CAS  Google Scholar 

  8. Riddle MA, Scahill L, King R, et al. Obsessive compulsive disorder in children and adolescents: phenomenology and family history. J Am Acad Child Adolesc Psychiatry 1990; 29(5): 766–72

    Article  PubMed  CAS  Google Scholar 

  9. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155(2): 264–71

    PubMed  CAS  Google Scholar 

  10. Palumbo D, Maughan A, Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Arch Neurol 1997; 54(4): 475–83

    CAS  Google Scholar 

  11. Cooper J. The Leyton Obsessional Inventory. Psychol Med 1970; 1: 48–64

    Article  PubMed  CAS  Google Scholar 

  12. Berg CZ, Rapoport JL, Flament M. The Leyton Obsessional Inventory-Child Version. J Am Acad Child Adolesc Psychiatry 1986; 25(1): 84–91

    Article  CAS  Google Scholar 

  13. Berg CZ, Whitaker A, Davies M, et al. The survey form of the Leyton Obsessional Inventory-Child Version: norms from an epidemiological study. J Am Acad Child Adolesc Psychiatry 1988; 27(6): 759–63

    Article  PubMed  CAS  Google Scholar 

  14. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46(11): 1012–6

    Article  CAS  Google Scholar 

  15. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46(11): 1006–11

    CAS  Google Scholar 

  16. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 844–52

    Article  PubMed  CAS  Google Scholar 

  17. Denckla MB. Neurological Examination. In: Rapoport JL, editor. Obsessive-compulsive disorder in children and adolescents. Washington, DC: American Psychiatric Press, 1989: 107–18

    Google Scholar 

  18. Shaffer D, Schonfeld I, O’Connor PA, et al. Neurological soft signs. Their relationship to psychiatric disorder and intelligence in childhood and adolescence. Arch Gen Psychiatry 1985; 42: 342–51

    CAS  Google Scholar 

  19. Kroll L, Drummond LM. Temporal lobe epilepsy and obsessive-compulsive symptoms. J Nerv Ment Dis 1993; 181(7): 457–8

    Article  PubMed  CAS  Google Scholar 

  20. van Balkom AJLM, van Oppen O, Vermeulen AWA, et al. A meta-analysis on the treatment of obsessive-compulsive disorder. Clin Psychol Rev 1994; 14: 359–81

    Article  Google Scholar 

  21. Foa EB, Grayson JB, Steketee GS, et al. Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol 1983; 51(2): 287–97

    Article  PubMed  CAS  Google Scholar 

  22. March JS, Mulle K, Herbei B. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 333–41

    Article  PubMed  CAS  Google Scholar 

  23. March JS, Mulle K. OCD in children and adolescents: a cognitive-behavioral treatment manual. New York (NY): The Guilford Press, 1998

    Google Scholar 

  24. March JS. Cognitive-behavioral psychotherapy for children and adolescent with OCD: a review and recommendations for treatment. J Am Acad Child Adolesc Psychiatry 1995; 34(1): 7–18

    Article  PubMed  CAS  Google Scholar 

  25. Dar R, Greist JH. Behavior therapy for obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15(4): 885–94

    PubMed  CAS  Google Scholar 

  26. Lenane M. Families in obsessive-compulsive disorder. In: Rapaport JL, editor. Obsessive-compulsive disorder in children and adolescents. Washington, DC: American Psychiatric Press, 1989: 237–52

    Google Scholar 

  27. Harris CV, Wiebe DJ. An analysis of response prevention and flooding procedures in the treatment of adolescent obsessive compulsive disorder. J Behav Ther Exp Psychiatry 1992; 23(2): 107–15

    Article  PubMed  CAS  Google Scholar 

  28. Hibbs ED, Hamburger SD, Lenane M, et al. Determinants of expressed emotion in families of disturbed and normal children. J Child Psychol Psychiatry 1991; 32(5): 757–70

    Article  PubMed  CAS  Google Scholar 

  29. Rapoport JL, Leonard HL, Swedo SE, Lenane MC. Obsessive compulsive disorder in children and adolescents: issues in management. J Clin Psychiatry 1993; 54 Suppl. : 27–9

    PubMed  Google Scholar 

  30. Riddle MA, editor. Pediatric psychopharmacology. I, II. Child and adolescent psychiatric clinics of North America. Philadelphia (PA): W.B. Saunders and Co., 1995

    Google Scholar 

  31. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997; 58 Suppl. 12: 18–22

    Google Scholar 

  32. Flament MF, Rapoport JL, Kilts C. A controlled trial of clomipramine in childhood obsessive compulsive disorder. Psychopharmacol Bull 1985; 21(1): 150–2

    PubMed  CAS  Google Scholar 

  33. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 1989; 46(12): 1088–92

    Article  CAS  Google Scholar 

  34. DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder — a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 45–9

    Article  PubMed  CAS  Google Scholar 

  35. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50(6): 441–7

    Article  PubMed  CAS  Google Scholar 

  36. Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacol Bull 1997; 33(4): 667–70

    PubMed  CAS  Google Scholar 

  37. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(6): 1062–9

    Article  PubMed  CAS  Google Scholar 

  38. Bodfish JW, Madison JT. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. Am J Ment Retard 1993; 98(3): 360–7

    PubMed  CAS  Google Scholar 

  39. Scahill L, Riddle MA, King RA, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7(2): 75–85

    Article  PubMed  CAS  Google Scholar 

  40. Perucca E, Marchioni E, Soragna D, et al. Fluoxetine-induced movement disorders and deficient CYP2D6 enzyme activity. Mov Disord 1997; 12(4): 624–5

    Article  PubMed  CAS  Google Scholar 

  41. Riddle MA, Claghorn J, Gaffney G, et al. A controlled trial of fluvoxamine for OCD in children and adolescents [abstract]. Psychopharmacol Bull 1996; 32(3): 399

    Google Scholar 

  42. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 342–8

    Article  PubMed  CAS  Google Scholar 

  43. Strauss WL, Layton ME, Hayes CE, et al. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 1997; 154(4): 516–22

    PubMed  CAS  Google Scholar 

  44. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997; 58 Suppl. 13: 9–13

    PubMed  Google Scholar 

  45. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10(2): 57–65

    Article  PubMed  CAS  Google Scholar 

  46. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992; 7 Suppl. 2: 37–41

    Article  Google Scholar 

  47. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280(20): 1752–6

    Article  PubMed  CAS  Google Scholar 

  48. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169(4): 468–74

    CAS  Google Scholar 

  49. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57(4): 507–33

    Article  PubMed  CAS  Google Scholar 

  50. Koponen H, Lepola U, Leinonen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997; 96(5): 343–6

    Article  PubMed  CAS  Google Scholar 

  51. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacology 1997; 17(4): 267–71

    Article  CAS  Google Scholar 

  52. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997; 7(3): 157–66

    Article  PubMed  CAS  Google Scholar 

  53. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993; 54 Suppl. : 16–26

    PubMed  Google Scholar 

  54. Liebowitz M. Copharmacy in treatment-resistant anxiety states [abstract]. American Psychiatric Association Annual Meeting: 1998 Jun 4; Toronto, Canada

  55. McDougle CJ, Goodman WK, Leckman JF, et al. Haioperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51(4): 302–8

    CAS  Google Scholar 

  56. Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol 1992; 7 Suppl. 1: 35–8

    Article  Google Scholar 

  57. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56(11): 526–8

    PubMed  CAS  Google Scholar 

  58. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58(3): 119–22

    Article  PubMed  CAS  Google Scholar 

  59. Alzaid K, Jones BD. A case report of risperidone-induced obsessive-compulsive symptoms [letter]. J Clin Psychopharmacol 1997; 17(1): 58–9

    Article  PubMed  CAS  Google Scholar 

  60. Dodt JE, Byerly MJ, Cuadros C, et al. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline [letter]. Am J Psychiatry 1997; 154(4): 582

    PubMed  CAS  Google Scholar 

  61. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57(7): 303–6

    PubMed  CAS  Google Scholar 

  62. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56(9): 423–9

    PubMed  CAS  Google Scholar 

  63. Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biol Psychiatry 1988; 23(2): 181–5

    Article  PubMed  CAS  Google Scholar 

  64. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am J Psychiatry 1984; 141(10): 1283–5

    PubMed  CAS  Google Scholar 

  65. Stern TA, Jenike MA. Treatment of obsessive-compulsive disorder with lithium carbonate. Psychosomatics 1983; 141: 1283–5

    Google Scholar 

  66. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy [see comments]. J Clin Psychopharmacol 1991; 11(3): 175–84

    Article  PubMed  CAS  Google Scholar 

  67. Pigott TA, Pato MT, L’Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11(4): 242–8

    Article  PubMed  CAS  Google Scholar 

  68. Pigott TA, L’Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12(1): 11–8

    Article  PubMed  CAS  Google Scholar 

  69. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990; 26(3): 285–90

    PubMed  CAS  Google Scholar 

  70. Figueroa Y, Rosenberg D, Birmaher B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8(1): 61–7

    Article  PubMed  CAS  Google Scholar 

  71. Wagner HR, Reches A, Fahn S. Clonazepam-induced up-regulation of serotonin-1 binding sites in frontal cortex of rat. Neuropharmacology 1985; 24: 953–6

    Article  PubMed  CAS  Google Scholar 

  72. Ross DC, Piggott LR. Clonazepam for OCD. J Am Acad Child Adolesc Psychiatry 1993; 32(2): 470–1

    Article  PubMed  CAS  Google Scholar 

  73. Leonard HL, Topol D, Bukstein O, et al. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994; 33(6): 792–4

    Article  PubMed  CAS  Google Scholar 

  74. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997; 154(1): 110–2

    PubMed  CAS  Google Scholar 

  75. Hollander E, Delgiudice-Asch G, Simon L, et al. Repetitive behaviors and D8/17 positivity. Am J Psychiatry 1997; 154(11): 1630–1

    PubMed  CAS  Google Scholar 

  76. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of Pediatric OCD and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1995; 34(3): 307–11

    Article  PubMed  CAS  Google Scholar 

  77. Leonard HL, Swedo SE, Garvey M, et al. Postinfectious and other forms of obsessive-compulsive disorder. Child Adolesc Psychiatric Clin NA 1999; 8(3): 497–511

    CAS  Google Scholar 

  78. Mittleman BB. Cytokine networks in Sydenham’s chorea and PANDAS. Adv Exp Med Biol 1997; 418: 933–5

    PubMed  CAS  Google Scholar 

  79. Allen AJ. Group A streptococcal infections and childhood psychiatric disorders: relationships and therapeutic implications. 1997; 8(4): 267–75

    Google Scholar 

  80. Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf 1997; 16(2): 118–32

    Article  PubMed  CAS  Google Scholar 

  81. Grady TA, Pigott TA, L’Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150(5): 819–21

    PubMed  CAS  Google Scholar 

  82. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150(4): 647–9

    PubMed  CAS  Google Scholar 

  83. Hollander E, Decaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990; 51(3): 119–23

    PubMed  CAS  Google Scholar 

  84. Erfurth A, Schmauss M. Monoamine oxidase inhibitors in the treatment of obsessive disorders. Two case reports and review of the literature [in German]. Nervenarzt 1993; 64(1): 70–2

    CAS  Google Scholar 

  85. Pine D, Shaffer D, Schonfeld IS. Persistent emotional disorder in children with neurological soft signs. J Am Acad Child Adolesc Psychiatry 1993; 32(6): 1229–36

    Article  PubMed  CAS  Google Scholar 

  86. Hollander E, Schiffman E, Cohen B, et al. Signs of central nervous system dysfunction in obsessive-compulsive disorder [see comments]. Arch Gen Psychiatry 1990; 47(1): 27–32

    Article  PubMed  CAS  Google Scholar 

  87. Nickoloff SE, Radant AD, Reichler R, et al. Smooth pursuit and saccadic eye movements and neurological soft signs in obsessive-compulsive disorder. Psychiatry Res 1991; 38(2): 173–85

    Article  PubMed  CAS  Google Scholar 

  88. Thienemann M, Koran LM. Do soft signs predict treatment outcome in obsessive-compulsive disorder? J Neuropsychiatry Clin Neurosci 1995; 7(2): 218–22

    PubMed  CAS  Google Scholar 

  89. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies [see comments]. J Clin Psychiatry 1994; 55 Suppl. : 11–7

    PubMed  Google Scholar 

  90. Alarcon RD, Libb JW, Spitler D. A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol. 1993; 13(3): 210–3

    Article  PubMed  CAS  Google Scholar 

  91. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995; 56(8): 368–73

    PubMed  CAS  Google Scholar 

  92. Jenike MA, Baer L, Minichiello WE, et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 1986; 143(4): 530–2

    PubMed  CAS  Google Scholar 

  93. Leonard HL, Swedo SE, Lenane MC, et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50(6): 429–39

    Article  PubMed  CAS  Google Scholar 

  94. Jefferson JW. Drug interactions — friend or foe? J Clin Psychiatry 1998; 59 Suppl. 4: 37–47

    PubMed  CAS  Google Scholar 

  95. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994; 9 Suppl. 3: 13–9

    Article  PubMed  Google Scholar 

  96. Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 1992; 149(11): 1592–4

    PubMed  CAS  Google Scholar 

  97. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45(6): 1211–4

    Article  PubMed  CAS  Google Scholar 

  98. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18(1): 2–9

    Article  PubMed  CAS  Google Scholar 

  99. Joos AA, Konig F, Frank UG, et al. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 1997; 30(6): 266–70

    Article  PubMed  CAS  Google Scholar 

  100. Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry 1997; 30(6): 272–3

    Article  PubMed  CAS  Google Scholar 

  101. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986; 21(11): 1067–71

    Article  PubMed  CAS  Google Scholar 

  102. Mitchell PB. Selective serotonin reuptake inhibitors: adverse effects, toxicity and interactions. Adverse Drug React Toxicol Rev 1994; 13(3): 121–44

    PubMed  CAS  Google Scholar 

  103. Vella JP, Sayegh MH. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 1998; 31(2): 320–3

    Article  PubMed  CAS  Google Scholar 

  104. Azaz-Livshits TL, Danenberg HD. Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 1997; 30(6): 274–5

    Article  PubMed  CAS  Google Scholar 

  105. Martin DE, Zussman BD, Everitt DE, et al. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol. 1997; 17(6): 451–9

    Article  PubMed  CAS  Google Scholar 

  106. Bergstrom RF, Goldberg MJ, Cerimele BJ, et al. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997; 62(6): 643–51

    Article  PubMed  CAS  Google Scholar 

  107. Campos MCR, Shavitt RG, Mercadante MT, et al. Early-onset OCD: a different subtype [abstract]? American Psychiatric Association Annual Meeting: 1998 Jun 4; Toronto, Canada

  108. Zohar J, Sasson Y. Treatment of obsesive-compulsive symptoms in schizophrenia. American Psychiatric Association Annual Meeting: 1998 Jun 4; Toronto, Canada

  109. Grados MA, Gerring JP, Bryan N, et al. Obsessive compulsive disorder in children and adolescent with closed head injury [abstract]. J Neuropsychiatry Clin Neurosci 1997; 9(1): 135

    Google Scholar 

  110. Swedo SE, Rapoport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham’s chorea. Am J Psychiatry 1989; 146(2): 246–9

    PubMed  CAS  Google Scholar 

  111. Rettew DC, Swedo SE, Leonard HL, et al. Obsessions and compulsions across time in 79 children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(6): 1050–6

    Article  PubMed  CAS  Google Scholar 

  112. Berg CZ, Rapoport JL, Whitaker A, et al. Childhood obsessive compulsive disorder: a two-year prospective follow-up of a community sample. J Am Acad Child Adolesc Psychiatry 1989; 28(4): 528–33

    Article  PubMed  CAS  Google Scholar 

  113. Warren W. A study of psychiatric inpatients and the outcome six or more years later. II. The follow-up study. J Child Psychol Psychiatry 1965; 6: 141–60

    Article  Google Scholar 

  114. Hollinsgsworth CE, Tanguay PE, Grossman L, et al. Long-term outcome of obsessive-compulsive disorder in childhood. J Am Acad Child Adolesc Psychiatry 1980; 19: 134–44

    Article  Google Scholar 

  115. Flament MF, Koby E, Rapoport JL, et al. Childhood obsessive-compulsive disorder: a prospective follow-up study. J Child Psychol Psychiatry 1990; 31(3): 363–80

    Article  PubMed  CAS  Google Scholar 

  116. Bolton D, Luckie M, Steinberg D. Long-term course of obsessive-compulsive disorder treated in adolescence. J Am Acad Child Adolesc Psychiatry 1995; 34(11): 1441–50

    Article  PubMed  CAS  Google Scholar 

  117. Thomsen PH, Mikkelsen HU. Course of obsessive-compulsive disorder in children and adolescents: a prospective follow-up study of 23 Danish cases. J Am Acad Child Adolesc Psychiatry 1995; 34(11): 1432–40

    Article  PubMed  CAS  Google Scholar 

  118. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48(10): 922–7

    Article  PubMed  CAS  Google Scholar 

  119. Lesch KP, Dietmar B, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31

    Article  PubMed  CAS  Google Scholar 

  120. Billett EA, Richter MA, King N, et al. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry 1997; 2(5): 403–6

    Article  PubMed  CAS  Google Scholar 

  121. Cruz C, Camarena B, King N, et al. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neurosci Lett 1997; 231(1): 1-4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    Marco A. Grados

  2. Division of Child & Adolescent Psychiatry, Johns Hopkins Medical Institutions, Department of Psychiatry and Behavioral Sciences, 600 North Wolfe Street, CMSC 338, Baltimore, Maryland, 21287-3325, USA

    Mark A. Riddle (Director)

Authors
  1. Marco A. Grados
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Riddle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark A. Riddle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grados, M.A., Riddle, M.A. Obsessive-Compulsive Disorder in Children and Adolescents. Mol Diag Ther 12, 257–277 (1999). https://doi.org/10.2165/00023210-199912040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199912040-00002

Keywords

Search

Navigation